Literature DB >> 29700105

Lung cancer staging: a concise update.

Ramón Rami-Porta1,2, Sergi Call1,3, Christophe Dooms4, Carme Obiols1, Marcelo Sánchez5, William D Travis6, Ivan Vollmer5.   

Abstract

Diagnosis and clinical staging of lung cancer are fundamental to planning therapy. The techniques for clinical staging, i.e anatomic and metabolic imaging, endoscopies and minimally invasive surgical procedures, should be performed sequentially and with an increasing degree of invasiveness. Intraoperative staging, assessing the magnitude of the primary tumour, the involved structures, and the loco-regional lymphatic spread by means of systematic nodal dissection, is essential in order to achieve a complete resection. In resected tumours, pathological staging, with the systematic study of the resected specimens, is the strongest prognostic indicator and is essential to make further decisions on therapy. In the present decade, the guidelines on lung cancer staging of the American College of Chest Physicians and the European Society of Thoracic Surgeons are based on the best available evidence and are widely followed. Recent advances in the classification of the adenocarcinoma of the lung, with the definition of adenocarcinoma in situ, minimally invasive adenocarcinoma and lepidic predominant adenocarcinoma, and the publication of the eighth edition of the tumour, node and metastasis classification of lung cancer, have to be integrated into the staging process. The present review complements the latest guidelines on lung cancer staging by providing an update of all these issues.
Copyright ©ERS 2018.

Entities:  

Mesh:

Year:  2018        PMID: 29700105     DOI: 10.1183/13993003.00190-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  21 in total

1.  Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer.

Authors:  M Majem; J Hernández-Hernández; F Hernando-Trancho; N Rodríguez de Dios; A Sotoca; J C Trujillo-Reyes; I Vollmer; R Delgado-Bolton; M Provencio
Journal:  Clin Transl Oncol       Date:  2019-06-06       Impact factor: 3.405

2.  The importance of the false-negative rate to validate a staging protocol for non-small cell lung cancer.

Authors:  Carme Obiols; Sergi Call; Ramon Rami-Porta
Journal:  Transl Lung Cancer Res       Date:  2019-12

3.  Efficient procedure planning for comprehensive lymph node staging bronchoscopy.

Authors:  Trevor K Kuhlengel; Rebecca Bascom; William E Higgins
Journal:  J Med Imaging (Bellingham)       Date:  2022-09-06

Review 4.  A narrative review of deep learning applications in lung cancer research: from screening to prognostication.

Authors:  Jong Hyuk Lee; Eui Jin Hwang; Hyungjin Kim; Chang Min Park
Journal:  Transl Lung Cancer Res       Date:  2022-06

5.  Assessment of Clinical Stage IA Lung Adenocarcinoma with pN1/N2 Metastasis Using CT Quantitative Texture Analysis.

Authors:  Haixu Zhu; Yanyan Xu; Nanxue Liang; Hongliang Sun; Zhenguo Huang; Sheng Xie; Wu Wang
Journal:  Cancer Manag Res       Date:  2020-07-28       Impact factor: 3.989

6.  Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study.

Authors:  Fei Xu; Zhu Zeng; Bing Yan; Yiqi Fu; Yilan Sun; Guangdie Yang; Lingfang Tu; Satoshi Watanabe; Salma K Jabbour; Sara Bravaccini; Francesca Fanini; Jianying Zhou; Yihong Shen
Journal:  Transl Lung Cancer Res       Date:  2021-04

7.  Computed tomography perfusion (CTP) in primary lung cancer: Results from a tertiary care centre.

Authors:  Mufeed Arimbrakkunnan; Pawan K Garg; Pushpinder S Khera; Binit Sureka; Poonam Elhence; Puneet Pareek; Nishant Kumar Chauhan; Taruna Yadav
Journal:  Lung India       Date:  2022 May-Jun

8.  Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer.

Authors:  Clementine Bostantzoglou; Marianthi Iliopoulou; Georgia Hardavella
Journal:  Breathe (Sheff)       Date:  2018-12

9.  Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma.

Authors:  Masaoki Ito; Yoshihiro Miyata; Shoko Hirano; Fumiko Irisuna; Kei Kushitani; Yuichiro Kai; Naoto Kishi; Yasuhiro Tsutani; Yukio Takeshima; Morihito Okada
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-03       Impact factor: 4.553

10.  Relationships and Qualitative Evaluation Between Diffusion-Weighted Imaging and Pathologic Findings of Resected Lung Cancers.

Authors:  Katsuo Usuda; Shun Iwai; Aika Yamagata; Atsushi Sekimura; Nozomu Motono; Munetaka Matoba; Mariko Doai; Sohsuke Yamada; Yoshimichi Ueda; Keiya Hirata; Hidetaka Uramoto
Journal:  Cancers (Basel)       Date:  2020-05-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.